Description: Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Home Page: www.cassavasciences.com
6801 N. Capital of Texas Highway
Austin,
TX
78731
United States
Phone:
512 501 2444
Officers
| Name | Title |
|---|---|
| Mr. Richard Jon Barry | CEO, President & Director |
| Mr. Eric J. Schoen | Chief Financial Officer |
| Mr. R. Christopher Cook J.D. | Senior VP, Company Secretary & General Counsel |
| Dr. James W. Kupiec M.D. | Chief Medical Officer |
| Dr. George Thornton Ph.D. | Senior Vice President of Technology |
| Mr. Michael Zamloot | Senior Vice President of Technical Operations |
| Dr. Michael Marsman Pharm.D. | Senior Vice President of Regulatory Affairs |
| Dr. Lindsay H. Burns Ph.D. | Senior Vice President of Neuroscience |
| Ms. Freda Nassif | Chief Commercial Officer |
| Jaren Landen | Chief Clinical Development Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 147.0588 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8795 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |